Cheesman D W, Schlegel R, Sagasay A M, Forsham P H
Endocrinology. 1983 Jan;112(1):269-76. doi: 10.1210/endo-112-1-269.
We synthesized a series of analogs of arginine vasotocin by systematically substituting each residue, and we then evaluated the anovulatory activity of these compounds in the rat, investigating the correlation between molecular structure and anovulatory, pressor, and antidiuretic activities. Substitution of the N-terminus cysteine with 3-mercaptopropanoic acid in arginine vasotocin and arginine vasopressin produced a 3- to 4-fold increase in both anovulatory and antidiuretic activity and only a 10% change in pressor activity. A similar substitution with lysine vasopressin produced no significant change in either anovulatory or antidiuretic potency; however, the pressor activity was reduced by half. Substitution of this cysteine in arginine vasotocin with 2-hydroxy-3-mercaptopropanoic acid produced an analog more potent in anovulatory activity than arginine vasotocin but less potent than [1-(3-mercaptopropanoic acid)]-arginine vasotocin. The most potent anovulatory analog synthesized was [1-(3-mercaptopropanoic acid)]-8-ornithine vasotocin, which gave a 10-fold increase in anovulatory activity, a 4-fold reduction in antidiuretic activity, and only a 10% increase in pressor potency when compared with arginine vasotocin. These data suggest that different receptors are involved in the anovulatory and antidiuretic responses, but that the anovulatory and pressor effects may be mediated through similar receptors. Further work is necessary to produce a peptide that possesses specific anovulatory activity.
我们通过系统地替换精氨酸血管催产素的每个残基,合成了一系列其类似物,然后评估了这些化合物在大鼠体内的无排卵活性,研究了分子结构与无排卵、升压和抗利尿活性之间的相关性。在精氨酸血管催产素和精氨酸加压素中,用3-巯基丙酸取代N端半胱氨酸,使无排卵和抗利尿活性均增加了3至4倍,而升压活性仅改变了10%。对赖氨酸加压素进行类似取代,无排卵或抗利尿效力均无显著变化;然而,升压活性降低了一半。用2-羟基-3-巯基丙酸取代精氨酸血管催产素中的该半胱氨酸,产生了一种在无排卵活性方面比精氨酸血管催产素更强但比[1-(3-巯基丙酸)]-精氨酸血管催产素更弱的类似物。合成的最有效的无排卵类似物是[1-(3-巯基丙酸)]-8-鸟氨酸血管催产素,与精氨酸血管催产素相比,其无排卵活性增加了10倍,抗利尿活性降低了4倍,升压效力仅增加了10%。这些数据表明,无排卵和抗利尿反应涉及不同的受体,但无排卵和升压作用可能通过相似的受体介导。需要进一步开展工作来制备具有特定无排卵活性的肽。